EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort

Yiyi Wang iD, Jingya Gao iD, Furong Li iD, Luyuan Li, Yue Xiao iD, Hongxiang Hu iD, Xiya Peng, Min Yang, Dan Hao iD, Wei Yan iD, Dengmei Xia iD, Wei Li iD

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17906 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Yiyi Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Adalimumab, Heterocyclic Compounds, 3-Ring, Antibodies, Monoclonal. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain limited. This study aimed to compare the real‐world effectiveness and safety of ADA, SEC, and UPA in PsA patients. We conducted a prospective cohort study using data from the PARWCH database. PsA patients treated with ADA, SEC, or UPA were included and followed at baseline, Week 4, Week 12, and Week 24. Skin responses were evaluated using PASI75/90. Joint outcomes—including peripheral and axial arthritis—were assessed with ACR, PsARC, and ASAS criteria. Patient‐reported pain, disease activity, and HAQ scores were also recorded. Adverse events (AEs) were monitored throughout treatment. MMRM and GLMM were used to analyze continuous and binary outcomes, respectively. A total of 187 PsA patients were included (SEC: 78; ADA: 66; UPA: 43). All three agents demonstrated comparable effectiveness in improving peripheral joint symptoms (ACR20: SEC vs. ADA, Coef = −0.29, p = 0.62; UPA vs. ADA, Coef = −0.29, p = 0.66) and axial involvement (ASAS20: SEC vs. ADA, Coef = −0.04, p = 0.81; UPA vs. ADA, Coef = −1.05, p = 0.23). UPA and SEC showed significantly greater effectiveness than ADA in improving skin lesions (PASI90: SEC vs. ADA, Coef = 1.84, p = 0.006; UPA vs. ADA, Coef = 1.53, p = 0.04). However, ADA was more effective in relieving pain compared to both UPA (Coef = 2.43, p < 0.001) and SEC (Coef = 1.21, p = 0.02). Over 24 weeks, 85 AEs were reported by 48 patients, with fatigue, rash, upper respiratory tract infection, and pruritus being the most common. No serious AEs occurred. In conclusion, UPA and SEC demonstrated balanced effectiveness across skin and joint domains, while ADA offered superior pain relief. These findings support personalized treatment strategies tailored to the clinical features of PsA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticAdalimumabHeterocyclic Compounds, 3-RingAntibodies, MonoclonalAntirheumatic AgentsHumansMaleFemaleMiddle AgedProspective StudiesAdultTreatment OutcomeSeverity of Illness IndexAgedAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

adalimumabpsoriasispsoriatic arthritissecukinumabtargeted therapiesupadacitinib

Substanzen

AdalimumabsecukinumabupadacitinibHeterocyclic Compounds, 3-RingAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China.
  • The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Dermatology, West China Second University Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Yiyi Wang, Jingya Gao, Furong Li, Yue Xiao, Hongxiang Hu, Dan Hao, Wei Yan, Dengmei Xia, Wei Li

Zitieren

APA

Wang, Y., Gao, J., Li, F., Li, L., Xiao, Y., Hu, H., Peng, X., Yang, M., Hao, D., Yan, W., Xia, D., & Li, W. (2025). Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17906

Vancouver

Wang Y, Gao J, Li F, Li L, Xiao Y, Hu H, et al. Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17906

BibTeX
@article{Wang2025,
  author = {Wang, Yiyi and Gao, Jingya and Li, Furong and Li, Luyuan and Xiao, Yue and Hu, Hongxiang and Peng, Xiya and Yang, Min and Hao, Dan and Yan, Wei and Xia, Dengmei and Li, Wei},
  title = {Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17906}
}
Kostenlos starten →